news in brief
US FDA bans APIs made by Fleming Labs
![US FDA bans APIs made by Fleming Labs](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/pharmaceutical-science/in-pharmatechnologist.com/headlines/ingredients/us-fda-bans-apis-made-by-fleming-labs/7494448-1-eng-GB/US-FDA-bans-APIs-made-by-Fleming-Labs.png)
The US regulator banned the drug and active pharmaceutical ingredient (API) firm this week, issuing it a 66-40 import alert. A 66-40 alert is issued when a firm is “not operating in conformity with current good manufacturing practices (GMP's).”
The Nawabpet plant – also called Unit I - is about 40km outside Hyderabad. It produces a range of drug ingredients, including anti-histamines, muscle relaxants and treatments for cardiac disorders.
The news comes less than a year after Fleming paid outstanding registration fees that had earned the facility a US Food and Drug Administration (FDA) in 2014.